We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Hematology-Oncology

Comparing CHOP and CHOEP/EPOCH Regimens in Aggressive Adult T-Cell Leukemia/Lymphoma: Insights from an International Cohort Study

MedXY Editorial Team•Sep 17, 2026•Hematology-Oncology
chemotherapysurvival outcomesAdult T-cell leukemia/lymphomaCHOPCHOEP/EPOCH

Highlight

  • CHOEP/EPOCH regimens show improved 3-year overall survival compared to CHOP in lymphomatous adult T-cell leukemia/lymphoma (ATL).
  • No significant survival benefit of CHOEP/EPOCH over CHOP was observed in acute ATL.
  • Overall response rates between regimens were not statistically different across ATL subtypes.
  • The study underscores the need for subtype-specific prospective clinical trials in aggressive ATL management.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Germline Lymphoma-Predisposing Variants: Influence on Age at Diagnosis and Survival Outcomes in Pediatric PatientsThis review synthesizes current evidence on germline lymphoma-predisposing variants, highlighting their impact on earlier cancer onset and variable survival rates in pediatric lymphoma patients, underscoring implications for genetic screeniSep 17, 2026Impact of Hypercortisolism Severity on Outcomes in Adrenocortical Carcinoma with Cushing’s SyndromeThis study reveals that the severity of hypercortisolism in adrenocortical carcinoma patients with Cushing’s syndrome correlates with higher metastatic risk and worse survival outcomes, highlighting its role as a marker of tumor aggressivenSep 15, 2026Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical TrialFive-year data from KEYNOTE-826 confirm pembrolizumab combined with chemotherapy as a durable, first-line treatment improving survival in persistent, recurrent, or metastatic cervical cancer without new safety concerns.Sep 15, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Angioembolization vs. Surgery in Penetrating Hepatic Trauma: Balancing Survival and Hospital Stay
In penetrating liver trauma, angioembolization offers survival outcomes comparable to surgery but is linked to longer hospital and ICU stays, highlighting the need for strategic patient selection and multidisciplinary care integration.
Sep 13, 2026
Impact of Conditioning Regimens on Pregnancy Outcomes in Female Survivors of Childhood and Adolescent Acute Leukemia: HSCT versus Conventional ChemotherapyThis multicenter study reveals that total-body irradiation (TBI) conditioning before hematopoietic stem cell transplantation severely compromises pregnancy outcomes compared to alkylating agents or conventional chemotherapy in female survivSep 12, 2026
Clinical Outcomes and Prognostic Factors in Lung Metastases Following Gastrectomy for Gastric CancerThis review summarizes the clinical characteristics, disease course, and survival outcomes of lung metastases after gastrectomy in gastric cancer patients, highlighting prognostic factors and the role of pulmonary metastasectomy.Sep 7, 2026